Recent Updates
Recently added Catalysts

Recurrent Cutaneous T-Cell Lymphoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$356Muniverse median $1.20B
Allocated capital$119M$356M competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank272/299crowding rank 273

Recurrent Cutaneous T-Cell Lymphoma is uncontested. Perspective Therapeutics (CATX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with VMT01 in phase 1.

There is no public comparable to price it against. CATX spreads its $356M market cap across 3 indications, so $119M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$119M of allocated capital sits in Recurrent Cutaneous T-Cell Lymphoma, ranking it 272nd of 299 indications by the money committed to it.

Companies developing drugs for Recurrent Cutaneous T-Cell Lymphoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CATXPerspective TherapeuticsVMT01Phase 11$356MNo3 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Recurrent Cutaneous T-Cell Lymphoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Recurrent Cutaneous T-Cell Lymphoma has one competitor and a median of $356M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Well-differentiated Pancreatic Neuroendocrine Tumor1 company · $119M · median $356MUncontestedRelapsed/Refractory Non-Hodgkin's Lymphoma1 company · $117M · median $351MUncontestedStage IV Merkel Cell Carcinoma1 company · $134M · median $134MUncontestedHigh-grade Serous Ovarian Cancer1 company · $98M · median $295MUncontestedB-Cell Acute Lymphoblastic Leukemia2 companies · $92M · median $221MOrphan cornerLow-Grade Serous Ovarian Carcinoma1 company · $90M · median $723MUncontestedEndometrioid Carcinoma1 company · $90M · median $723MUncontestedT-Cell Lymphoblastic Leukemia/Lymphoma2 companies · $149M · median $374MOrphan corner

Recurrent Cutaneous T-Cell Lymphoma pipeline questions

Which biotech companies are developing drugs for Recurrent Cutaneous T-Cell Lymphoma?

Perspective Therapeutics (CATX, VMT01, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Recurrent Cutaneous T-Cell Lymphoma.

How advanced is the Recurrent Cutaneous T-Cell Lymphoma pipeline?

Of the 1 clinical-stage programme in Recurrent Cutaneous T-Cell Lymphoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Recurrent Cutaneous T-Cell Lymphoma?

No. CATX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Recurrent Cutaneous T-Cell Lymphoma, which is why the indication is classified as uncontested.

When is the next Recurrent Cutaneous T-Cell Lymphoma catalyst?

The next dated catalyst in Recurrent Cutaneous T-Cell Lymphoma is CATX on 23 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map